Antisense gene therapy using molecules such as antisense oligodeoxynucleotides, siRNA or miRNA is a very promising strategy for the treatment of neoplastic diseases. It can be combined with other treatment strategies to enhance therapeutic effect. In acute leukemias, overexpression of the antiapoptotic gene BCL2 is observed in more than 70% of cases. Therefore, reduction of the Bcl-2 protein level could, in itself, prevent the development of cancer or could possibly help sensitize cancer cells to apoptosis inducers. The main objective of our work is to develop therapeutic liposome formulations characterized by high transfection efficiency, stability in the presence of serum, as well as specificity and toxicity for target (leukemic) cells. Each of our liposomal formulations consists of a core composed of antisense oligonucleotides complexed by either cationic lipid, DOTAP, or a synthetic polycation, polyethyleneimine, encapsulated within liposomes modified with polyethylenoglycol. In addition, the liposomal shells are enriched with covalently-bound antibodies recognizing a well characterized bio-marker, CD20, exposed on the surface of leukemia cells. The resulting immunoliposomes selectively and effectively reduced the expression of BCL2 in target cells. Model animal experiments carried out on mice-engrafted tumors expressing the specific marker showed high efficiency of the liposome formulations against specific tumor development. In conclusion, we show that lipid formulations based on a polyplex or lipoplex backbone additionally equipped with antibodies are promising non-viral vectors for specific oligonucleotide transfer into human tumor cells.
Introduction
Cancer, a large family of diseases, remains a global health problem and one of the major causes of death worldwide. Whilst it has been traditionally considered a terminal disease, there is now a growing opinion that it could become a manageable chronic disease, rather than a terminal acute illness. However, this requires long-term pharmacological intervention and has forced major shifts in cancer therapy approaches, particularly in recent years, resulting in new and more effective therapeutic strategies. Nucleic acid molecules such as antisense oligonucleotides (DNA or RNA), small interfering RNAs (siRNA, miRNA) or oligonucleotides with catalytic activity (DNAzymes, ribozymes) can be used to inhibit the expression of particular genes either as a monotherapy, or in combination with other non-gene therapeutic agents, to enhance their effectiveness [1, 2] .
Antisense oligonucleotides (asODNs) usually consist of [15] [16] [17] [18] [19] [20] nucleodides which are complementary to their target mRNA or the DNA sequence of a particular gene or its promoter. Two major mechanisms of antisense activity have been described. The first is the activation of RNase H, which digests the mRNA moiety of a DNA-RNA heteroduplex. Moreover, asODNs that do not induce RNase H activity can hybridize to mRNA and block its access to the ribosome. Antisense oligonucleotides may also bind to DNA sequences to form triplehelical structures, thus distorting transcription [3] [4] [5] .
Although the idea to reduce translation by oligonucleotides complementary to mRNA is simple, several issues need to be solved for successful application of antisense molecules as therapeutics. Extra-and intracellular obstacles must be overcome in order to achieve selective and effective nucleic acid delivery into target cells and tissues. These include anatomical barriers such as epithelium, endothelium and the extracellular matrix. Surrounding cells also may prevent nucleic acids to reach target cells. In addition, various nucleases are present in the blood and, therefore, protection against enzymatic degradation of the nucleic acids is also crucial [6] . Solving these problems can be achieved by delivery of a therapeutic DNA or RNA fragment to the target cell in vivo by the utilization of a suitable nanocarrier system [7, 8] Over the last few years a wide variety of delivery systems for asODNs have been developed and many of these are currently undergoing clinical trials. The potential of liposomes as a delivery tool for gene transfer has been extensively studied for many years and is of particular focus, due to the recent emergence of encouraging data. They are an interesting alternative to viral vectors, which are most effective but characterized by numerous drawbacks, such as high risk of immunogenicity and the possibility of unwanted insertion mutations, which eliminate them at the moment from therapeutic application [9] [10] [11] . Liposomes are artificial lipid-based vesicles made up of one or more lipid bilayers encapsulating internal aqueous compartments which can be loaded with nucleic acid and facilitate its transfer into the cell. Delivery of nucleic acids into cells occurs primarily liposome uptake via endocytosis and subsequent fusion processes are involved in the release of the nucleic acid complexes from the endosomal compartment into the cytosol [7, 12] .
Targeted vectors are increasingly favored tools for specific delivery of antisense oligonucleotide-based therapeutics into cancer cells. This is achieved by functionalizing the carrier with targeting moieties that exhibit high-affinity towards specific tumor cells. Monoclonal antibodies [13] [14] [15] , antibody derivatives [13, 14, 16] , peptides [17, 18] , and aptamers [19, 20] , designed ankyrin repeat proteins (DARPins) [21] and small targeting molecules [22, 23] can be attached to liposomes and each of them have been reported to exhibit active targeted delivery [24] . In this regard, chemical modifications of polyethylenoglycol (PEG) residues are particularly suitable for conjugation of targeting moieties to the surface of liposomes [25] .
Here, we present two liposomal formulations designed to carry nucleic acids, which can be easily targeted to cells exposing cancer-specific markers recognized by targeting molecules conjugated to the liposome surface. One of the formulations is based on a DOTAP (1,2-dioleoyl-3-trimethylammonium-propane)-asODNs complex (tL-D) and the other is based on a PEI (polyethylenimine)-asODNs complex (tL-P). Both complexes are encapsulated in a PEG (polyethyleneglycol)-modified liposomal coat. Attachment of targeting molecules was achieved via chemical coupling of antibodies to the maleimide groups present on the PEG-modified lipid. These formulations fulfill the criteria of size, stability, specificity and reasonably high efficacy against specific types of cancer cells.
Materials and methods

Materials
DOTAP (1,2-dioleoyl-3-trimethylammonium-propane (chloride salt) N 99%; DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine); HEPC (L-α-phosphatidylcholine, hydrogenated (egg, chicken) N99%; DC-CHOL (3ß-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol hydrochloride) N99% were purchased from Avanti Polar Lipids, Inc. (USA); DSPE-PEG (N-(Carbonyl-methoxypolyethyleneglycol2000)-1,2-distearoyl-sn-glycero-3 phosphoethanolamine, sodium salt) N99%; DSPE-PEG-Mal (N-[(3-Maleimide-1-oxopropyl)aminopropyl polyethyleneglycol-carbamyl] distearoylphosphatidyl-ethanolamine) N99% were purchased from NOF Corporation (Japan). Further reagents were: OPD, o-phenylenediamine (Sigma Aldrich (Germany); PEI (Polyethylenimine) (Polyscience, Inc. USA); BCA Protein Assay Reagent (Thermo Scientific, USA); Hanks liquid medium (Institute of Immunology and Experimental Therapy, Polish Academy of Science, Wroclaw, Poland); Matrigel (BD, Immunogen); plasmid pMaxGFP (Lonza); Rituximab, therapeutic anti-CD20 antibodies MabThera (Roche); antihuman Bcl-2 mouse monoclonal antibodies (Santa Cruz, USA and Abcam, USA); anti-human Actin goat polyclonal antibodies (Santa Cruz, USA); horseradish peroxidase-conjugated goat anti-mouse and donkey anti-goat IgG (Santa Cruz, USA); Sepharose 4B and Sephadex G-100 (Sigma-Aldrich); mitoxantrone 2 mg/ml (Hospira, UK, Ltd.); calcein (POCH S.A.R); DNase I (RNase-free, MnCl2) (Fermentas, Thermo Scientific); MTT (Sigma-Aldrich, Life Science); DiD 1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine (Thermo Fisher Scientific), DiO 3,3′-dioctadecyl-oxacarbocyanine perchlorate (Thermo Fisher Scientific); Traut's reagent ≥ 98% (TLC) (Sigma-Aldrich, Life Science); agarose (Prona); Ficoll Paque (GE Healthcare Life Technologies, Inc.). Antisense oligonucleotides (asODNs) anti-BCL2 mRNA of the following sequence: 5ʹ TCT CCC AGC GTG CGC CAT 3ʹ and scrambled sequence: 5ʹ CAG CGT GCG CCA TCC TTC CC3ʹ were synthesized by Genomed, Poland.
Cells
Human Daudi (CCL-213) and Raji (CCL-86) B-cell lines and white blood cells isolated from peripheral blood (permission number KB -542/2011 of the Ethics Committee at the Medical University of Wroclaw) were used as a model of target cells. Jurkat T-cells, HL60 and HEL cell lines were used as negative (CD20-) control cells. All cell lines were obtained from the Cell Culture Collection, Institute of Immunology and Experimental Therapy, Polish Academy of Science at Wroclaw. Cells were cultured in vitro in RPMI 1640 medium (Lonza) supplemented with 10% fetal bovine serum (Lonza), 2 mM glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin (Lonza) at 37°C in a humidified atmosphere.
Liposome preparations
All types of liposomes studied in this report, prepared as described below, are listed in Table 1 , as are abbreviations of the control molecules used.
L-D Liposomes
The formation of DOTAP/asODN complexes was carried out by using a Blight and Dyer extraction [26] in a glass test tube. Cationic lipid, DOTAP (2 mg), was diluted in 150 μl of chloroform to which 400 μl of methanol was added, followed by 100 μg of ODNs or plasmid DNA (pMaxGFP Lonza) diluted in 150 μl of H 2 O. The mixture was incubated for 40 min at room temperature. Subsequently, 300 μl of chloroform and 300 μl of H 2 O were added, and the tube was centrifuged for 8 min at 800 ×g, at room temperature, followed by centrifugation and removal of the upper aqueous phase. Chloroform solutions of HEPC, DOPE, DC Cholesterol, DSPE-PEG and DSPE-PEG-Mal were premixed together in a weight ratio of 2.8:1:0.4:0.8:0.34 and then added to the remaining lower organic phase. Then, 1 ml of PBS was added to the mixture, and the resulting mixture was sonicated for 1 min to obtain a stable emulsion. In the case of the fluorescently labeled liposomes, DiD was added to the emulsion after the sonication step at a final concentration of 0.1 mol%. The organic solvent was evaporated under gaseous N 2 and vacuum-dessicated for at least 2 h. The gel phase was hydrated with 1 ml of PBS for 1 h by gentle stirring at room temperature. The resulting liposome suspension was then extruded 10 times through polycarbonate filters with pore sizes of 400, 200 and 100 nm in a sequential way. This protocol typically yielded 1 ml of liposomes at a final lipid concentration of 10 mg/ml containing 90 μg ODNs or plasmid DNA.
L-P liposomes
In order to prepare polyplexes, 100 μl of asODNs dissolved in water at 1 μg/μl were mixed with 200 μl of linear PEI (2500 Da) solution in water to obtain a N/P (PEI/DNA) ratio of 5:1. 100 μl of 10× PBS was then added and the mixture made up with water to 1 ml. The mixture was then incubated at room temperature for 30 min. Chloroform solutions of lipids HEPC, DOPE, DC-Cholesterol, DSPE-PEG and DSPE-PEGMal, in a weight ratio of 2.8:1:0.4:0.8:0.34 were premixed together, dried under a stream of nitrogen and kept under vacuum for at least 2 h to completely remove the solvent. The lipids were then hydrated with the 1 ml asODNs:polyethylenimine complex in PBS. As described above, in the case of fluorescently labeled liposomes, DiD was added to the mixture at a final concentration of 0.1 mol%. The liposomal suspension was then extruded through a series of polycarbonate filters of 400, 200 and 100 nm pore size, respectively. This protocol typically yielded 1 ml of liposomes at a final concentration of 8 mg/ml of lipids containing 90 μg of ODNs or plasmid DNA.
tL-D and tL-P liposomes
In order to attach the respective targeting-antibody to the liposomal surface, free amino groups on the antibodies were thiolated by exposure to Traut's reagent for 4 h at 4°C in PBS. The Traut's reagent was removed by dialysis into PBS buffer. The thiolated antibody was incubated for 24 h with a suspension of L-D or L-P liposomes in PBS containing DSPE-PEG-Mal in the liposomal coat. The specific reaction conditions were designed to achieve a molar ratio of 13:1 for the DSPE-PEG-Mal in the liposomal coat relative to the amount of IgG used. Unbound antibodies were separated from liposomes via size-exclusion chromatography on a Sepharose 4B column (1.25 × 25 cm) and the final antibodycoated liposomes equilibrated in PBS. A schematic representation of the preparations is included in Fig. 1. 2.3.4. PE/PC (60/40) non-PEGylated control, empty liposomes of 100 nm in diameter These liposomes were prepared by a simple procedure involving hydration of dry lipid film prepared from the 60:40 mixture of PE and HEPC (60:40 by weight) in PBS and systematic extrusion through Nucleopore filters, as was described above.
Determination of the antibody fraction attached to the liposome surface
A 96-well plate dedicated for ELISA (Greiner Bio One) was exposed to 4 μg of polyclonal rabbit anti-human IgG (Jackson ImmunoResearch) in 100 μl of PBS per well. The plate was incubated overnight at 4°C, washed, and the coated surface was then blocked with 5% non-fat milk in PBS. Then tL-D or tL-P immunoliposomes were added and incubated for 1 h at 37°C. Subsequently, the plate was washed and incubated for 45 min with a secondary antibody, namely rabbit antimouse IgG conjugated with HRP (Jackson ImmunoResearch), at a dilution of 1:5000. After further washing with PBS, HRP substrate (0.05% o-phenylenediamine (w/v) and 0.1% H 2 O 2 in citrate buffer, pH 5.0) was added. The result was read on a multiwell plate reader (Rayto) at a wavelength λ = 490 nm.
Liposome size and zeta potential
The mean diameter, polydispersity index and zeta potential of the prepared liposomes were obtained by using a Zetasizer Nano-ZS (Malvern Instruments, Malvern, UK).
Calcein release
L-D or L-P liposomes loaded with 30 mM calcein were prepared without the DOTAP-DNA or PEI-DNA complexes according to the standard procedure until the hydration of gel phase of L-D or dried lipid film of L-P. The liposomes were rehydrated in 30 mM calcein solution after which the lipid suspension was frozen in liquid nitrogen and thawed at 56°C. After 10 such freeze-thaw cycles, free calcein was removed by passing the liposome suspension through a Sephadex G-100 column (12 × 1 cm) and liposomes were downsized by the extrusion. Stability of barrier properties of liposomal shells upon 0.5-8 h exposure to 50% human serum at a temperature of 37°C was examined. The fluorescence of the calcein was measured with a (Carry Eclipse, Varian) spectrofluorometer at λex = 490 nm and λem = 520 nm. Calcein leakage was calculated according to the following formula: % Release = (F t − F 0 ) / (F total − F 0 ) × 100, where F t was the fluorescence of calcein after incubation with serum at time t = 0.5-8 h, F 0 was the spontaneous leakage at time t and F total was the fluorescence of calcein released from liposomes solubilized in 10% Triton X-100.
Protective properties of the liposome formulations against nucleic acid digestion by DNases
Liposomal suspensions containing 1 μg of plasmid DNA (pDNA) that had been stored for one year were incubated with 0.1 U of DNase I for 10 min at 37°C. After this time the DNase I was inactivated by heating at 65°C for 10 min in the presence of 50 mM EDTA, pH 7.5. In addition, the protective properties of liposome preparations against DNases was examined via exposure of liposomes to 50% human serum for incubation periods ranging from 1 to 8 h at a temperature of 37°C. For both assays, liposomes were subsequently separated on a Sepharose 4B microcolumn in order to remove the DNase I or serum proteins, respectively. The purified liposomes were solubilized with 10% Triton X-100 and analyzed by 1% agarose gel electrophoresis. As a positive control, liposomes were disrupted with Triton X-100 before incubation with DNase I or serum.
Toxicity assay
Toxicity assay was performed using the MTT assay in a 96-well plate format. Cells in the logarithmic growth phase at 1 × 10 5 /ml were incubated for 48 h with increasing concentrations of liposomes, MTO, or both. At the indicated time, 200 μg of MTT in a volume of 100 μl was added to the cells and incubated for 4 h at 37°C. The plates were then centrifuged at 1000 × g for 10 min. The supernatant was carefully removed from each well, and crystals of formazan were dissolved in DMSO at 50 μl/well. The absorbance was read on a multiwell plate reader at a wavelength of λ = 490 nm.
Based on the linear fragment of the cell-survival curves, the Inhibitory Concentration (IC) values were determined. The IC10 (first inhibitory concentration) and IC50 (half maximal inhibitory concentration) values represent the concentrations of a toxic agent which reduces the viability of the cell population by 10% and 50% respectively, compared to nontreated control.
Hemolysis assay
Human peripheral blood of healthy volunteers was collected into anti-coagulant (EDTA)-containing test tubes (Sarstedt S-Monovette R )
and centrifuged at 800 ×g for 10 min at 4°C. The supernatant (plasma) and the layer of leukocytes were removed and the pellet of erythrocytes was washed three times with 155 mM NaCl in 10 mM Tris-HCl pH 7.4 (TBS) and then centrifuged at 800 ×g for 10 min at 4°C. Then, 30 μl of a 50% suspension of erythrocytes (~7 × 10 7 cells) in TBS were suspended in 1 ml of the same buffer and incubated with increasing concentrations of liposomes (0.1-2 mg/ml) at 37°C for 2 h. Hemolytic activity was determined based on the concentration of hemoglobin (absorbance at λ = 570 nm) released from the erythrocyte suspension. In a control experiment, erythrocytes were suspended in TBS for 2 h at 37°C, while 100% hemolysis was determined by the dilution of the same amount of erythrocyte suspension in distilled water and incubated as above. To calculate the leakage of hemoglobin, the following formula was used: % Hemolysis = (H t − H 0 ) / (H total − H 0 )× 100, where H t was the absorbance of the 800 ×g supernatant of the erythrocyte suspension obtained after incubation with liposomes, H total was the absorbance of the supernatant of erythrocyte suspension obtained after incubation in water and H 0 was the absorbance of hemoglobin without liposomes.
Selectivity of targeted liposome-cell interaction
Jurkat T cells (0.5 × 10 6) were incubated with 5 nM DiO overnight in a humidified atmosphere and mixed with identical number of Daudi cells and were then incubated with 0.1 mg/ml DiD-labeled targeted (t-L), untargeted (L) or irrevelant IgG conjugated liposomes (IgG-L) for 1 h at 37°C. Immediately after the incubation unbound liposomes were removed by centrifugation and washing in PBS. Flow cytometry (BD FACS Calibur, BD Biosciences) was used to quantify the targeting potential of immunoliposomes. Cells were analyzed for DiO (530 nm, FL-1) and DiD fluorescence (633 nm, FL-4) based on 10,000 counts for each population. Mean fluorescence intensity as positive cell percentages were determined.
Bcl-2 protein level determination
To assess the effect of the proposed carriers on Bcl-2 expression, Daudi cells in the logarithmic growth phase were harvested, washed, aliquoted into 12-well multi-plates (1 × 10 6 cells/ml) and incubated for 48 h with liposomes. At the indicated times, cells were harvested and lysed.
Apoptosis determination
Cells ( 
Cytokine assay
Human peripheral mononuclear blood cells (2 × 10 6 cells/ml) were incubated with 5 μg/ml of free asODNs anti-BCL2 or free 'scrambled' ODNs and the same dose of ODNs encapsulated in tL-D or tL-P liposomes (0.5 mg liposomes/ml) for 24 and 48 h in a humidified atmosphere. At the indicated times, cells were centrifuged and supernatants were collected. Levels of interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) were measured using a Human IL-6 Quantikine ELISA Kit and a Human TNF-alpha Quantikine ELISA Kit (R&D Systems, UK), according to the manufacturer's instructions. Measurements were performed using a microplate reader (BMG Labtech, Poland). The results were expressed as the ratio of protein weight/supernatant volume (w/v).
Animals
Seven to eight-week-old male NOD/SCID mice (weighing 20-25 g) were obtained from the Children's Clinic Hospital of the Jagiellonian University at Kraków and maintained under standard pathogen-free (SPF) conditions. Animal experiments were approved by the First Local Committee for Experiments with Laboratory Animals, Wroclaw, Poland.
Circulation time and biodistribution
NOD/SCID mice-bearing human Burkitt's lymphoma with a mean tumor volume of 1000 mm 3 were administered in the lateral tail vein with DiD-labeled (0.1 mol%) liposomal preparations of tL-D, tL-P and control L-P, L-D, and PE/PC (L) in a volume of 10 μl per 1 g of body weight. Mice were sacrificed and blood was collected from the orbital sinus into a sample tube without EDTA using a capillary at 1, 8 and 24 h after administration of liposomes, and the collected blood then incubated for 2 h at room temperature. Plasma was separated by centrifugation for 5 min at 2000 ×g at room temperature. The fluorescence of DiD in the plasma was measured using a Cary Eclipse (Varian) spectrofluorometer at λ ex = 644 nm and λ em = 665 nm. The results were calculated as percent of DiD fluorescence, assuming 100% DiD fluorescence at the initial time (immediately after injection). In order to determine the localization of liposomes in CD20 + tumors, mice were sacrificed after 4 and 24 h post-injection and tumors were removed and washed. Analysis of DiD fluorescence intensity associated with liposomes in tumors was carried out using the Carestream version X instrument (FX Pro Carestream, USA), ex. = 630 nm, em. = 700 nm. Focal plane: 0.0, f-stop: 2.80. Exposure time was 10 s.
In vivo study of antitumor properties of immunoliposomes in mice bearing tumor xenografts
Liposome formulations were prepared in PBS as described above and administered to mice at a dose described in Table S1 , Supplementary Material. Daudi cells cultured in vitro, as described before, were suspended in medium (Matrigel:Hanks liquid ratio of 1:1) and injected subcutaneously (s.c.) in the left flank of each animal (5 × 10 6 cells in 0.2 ml medium/mouse). When the tumor volume reached 50-70 mm 3 , the animals were randomly divided into six equal groups with eight mice in each. Each group was injected with either the tL-D, tL-P, tL-Dsc, tL-Psc or t intravenously (i.v.) into the tail vein of the animal three times at weekly intervals. When used, MTO was administered intraperitoneally (i.p.) at a dose equivalent to 0.3 mg/kg body mass. The control group received PBS. A detailed list of treatments received by each group of animals is presented in Table S1 . Therapeutic efficacy for each treatment was assessed as a reduction of tumor volume of the treated mice compared to the control groups i.e. those which did not receive tL-D or tL-P. The tumor volume was monitored over the course of the experiment, with measurements performed three times per week during 70 days of experiment. The tumor volume was calculated according to the ellipsoid volume formula: tumor volume (mm 3 ) = (a 2 × b) / 2, where a = small tumor diameter in millimeters (width) and b = large tumor diameter in millimeters (length). The average body-weight change (BWC) in all of the groups was calculated using the formula BWC = (ABWn/ABW1) × 100-100%, where ABWn is the average body weight on day 'n' of the experiment (during treatment), and ABW1 is the average body weight on the first day of treatment.
Data analysis
Statistical analysis was performed using Statistica version 7.1 software (StatSoft, Tulsa, OK, USA). Values were expressed as means ± S.E. for all experiments. Significance of differences between the treatments and the control were examined by the Kruskal-Wallis analysis of variance multiple-comparison P-value test. All tests of statistical significance were two-sided, and p b 0.05 were considered as statistically significant.
Results
Stability of the liposomal formulations
3.1.1. The physicochemical properties of the liposomal formulations are stable during long-term storage It is assumed that, for efficient extravasation from the fenestrations in leaky vasculature of tumor, liposomes designed for in vivo applications should retain a diameter much less than 400 nm [28, 29] and demonstrate low polydispersity. The particle size in the case of both formulations presented here did not exceed a diameter of approximately 150 nm, even after attachment of antibodies to their surface and the PDI (the polydyspersity index) [27] was lower than 0.03 for both formulations. Both formulations were stable in terms of particle size during long-term storage as a suspension or in the form of a freeze-dried powder ( Fig. 2A) . Both formulations were also characterized by a small positive zeta potential in water and this parameter also did not change substantially during the 12 month storage period, either as a suspension or in the form of freeze-dried powder (Fig. 2B) . The effectiveness of the nucleic acid encapsulation within the presented liposomal constructs was rather high, about 90%, compared to the total amount added to the mixture during the preparation procedure. In this case, it means that 1 mg of L-D liposomes contains approximately 9 μg of ODNs or plasmid DNA and 1 mg of L-P liposomes contains approximately 11.25 μg of ODNs or plasmid DNA. Moreover, our liposomal formulations remained stable in terms of their nucleic acid content even after 12 months of storage (Fig. 2C) . In summary, the diameter of liposomes of both formulations increased maximally by 20 nm and zeta potential changed in the range 5 mV over a 12 month storage period. Formulations also maintained a very high (over 80%) content of nucleic acids during one year storage, both in the form of a freeze-dried powder and suspensions.
The average amount of antibodies conjugated to the liposomal envelope was equal to 10.8 ± 1.4 μg/mg liposomes, as determined by ELISA. Immunoliposomes tL-D and tL-P containing attached anti-CD20 antibodies were stable as a suspension in terms of particle size (increase in the particle diameter was by 20 ± 3.8 nm, n = 4) during 12 months of storage. Zeta potential changed in the narrow range 1.8 ± 0.26 mV. The attachment of antibody to the surface of tL-D and tL-P liposomes had no effect on the liposome stability and content of nucleic acid, even after 12 months of storage as a suspension.
Liposomal bilayer is stable in the presence of human plasma and serum
The resistance of the liposomal bilayer against many different active proteins in plasma, such as components of the complement system or soluble enzymes, including nucleases, plays a major role in maintaining the stability of the proposed drug carriers and their function as protectors of active substances loaded internally. As shown in Fig. 2D , both liposomal formulations are stable in the presence of 50% human plasma. Calcein leakage is lower than 10%, even after 8 h of incubation, which confirms rather high stability of liposomal coat.
Liposomes effectively protect encapsulated plasmid DNA against DNases
The chemical nature of nucleic acids necessitates a suitable carrier system as protection from enzymatic digestion and without changing their therapeutic properties, as well as enabling efficient delivery into targeted cells. To test the protective features of the proposed liposomal formulations, both were incubated in the presence of commercial DNase I. In Fig. 2E and F the data for liposomes stored for 12 months are presented. As can be seen, lipid bilayers of L-D and L-P liposomes effectively protect plasmid DNA against DNase I (Fig. 2 E) . Moreover, the liposomal formulations were incubated with 50% human serum in order to test their resistance against lytic factors and nucleolytic enzymes present in serum. Both formulations exhibit high protective properties of encapsulated DNA against serum nucleases (Fig. 2F) .
Efficiency of liposomes in vitro
3.2.1. The liposome coat shows only limited toxicity 3.2.1.1. The hemolytic activity against human erythrocytes. One of the elements of non-specific cytotoxic activity, an important parameter of a potential liposomal drug carrier, is the hemolytic activity associated with the treatment itself. Hemolytic activity of liposomes was assessed by examining the leakage of hemoglobin from erythrocytes after incubation with L-D and L-P containing control plasmid DNA. As can be seen, the leakage of hemoglobin was lower than 10% after 4 h of incubation with liposomes (Fig. 3A) , which suggests a very low level of hemolytic activity for these preparations.
3.2.1.2. Non-specific cytotoxicity towards non-target cell lines. In principle, the carrier for a drug, should not be toxic to non-target cells. The cytotoxic activity of L-D and L-P liposomes containing control plasmid DNA was tested via an MTT assay on several cell lines, namely, Jurkat T, HEL, and HL60 cells as well as white blood cells (WBC) isolated from the peripheral blood of healthy volunteers (Fig. 3B) . Based on the initial linear portion of the cell-survival curves, IC10 values were calculated. Both liposomal formulations exhibited low non-specific cytotoxic activity, estimated on the basis of IC10 values, ranging between 0.2-1 mg/ml. The viability of each of the cell populations analyzed was reduced maximally by 30% after incubation with the highest concentration of liposomes (2 mg/ml) carrying control plasmid DNA.
tL-D and tL-P show specific cytotoxicity either alone or in combination with a cytostatic drug
We investigated the cytotoxicity of the tL-D and tL-P immunoliposomal preparations towards target Daudi (CD20+) versus control Jurkat T (CD20-) cell lines. The results, presented in Fig. 4A , indicate that increasing concentrations of the liposomal formulations significantly reduce survival of target cells in culture. This effect is much stronger towards the CD20 + expressing Daudi cells than towards Jurkat T cells, which do not express this antigen. These experiments were also confirmed by the results obtained from the selectivity of interaction of DiD-labeled immunoliposomes with target cells mixed with non-target cell population (Fig. 4 B) .
Molecules, such as antisense oligodeoxynucleotides can be used to inhibit particular gene expression in monotherapy, or, in combination with other therapeutic agents to enhance the effectiveness of nongene therapy. Thus, the efficiency of our liposomal formulations in a combined treatment with mitoxantrone (MTO) was examined. Table 2 presents effective doses of liposomes against 50% of the treated population (IC50) and 90% (IC90), either alone or in the presence of 12.5 nM MTO. As can be seen, liposomal formulations exerted a stronger effect in combination with MTO than liposomes alone, with the corresponding IC50 values about two-fold lower for the liposomes in the combination therapy compared to liposomes alone (Table 2) . It should also be noted that long-term storage of both formulations did not substantially affect their specific cytotoxicity. The increase in IC50 values in both cases was not greater than 10% (Table 2 , values in parentheses). We noted high specificity of tL-cell surface interactions. Approximately 5-9% of Jurkat T and almost all Daudi cells in mixed population emitted DiD fluorescence, resulting from binding of tL indicating that targeting efficiency of tL-P towards Daudi cells was considerably higher. The interaction of tL-P with target cells was also much higher when compared with this of untargeted (L) or liposomes bearing irrelevant immunoglobulin (IgG-L) (Fig. 4B) . These data indicate a much higher effectiveness of interaction of liposomes coated with specific antibody with target cells. Similar results were obtained in confocal microscopy observations of target and non-target cells after incubation with immunoliposomes (Fig. S3) . A certain level of "nonspecific" interactions of immunoliposomes with nontarget cells (Fig. 4B) is associated with the rather high affinity of untargeted liposomes of similar composition to cells growing in suspension [30] . This relatively high cell surfacebinding activity also visible in vitro cytotoxicity Fig. 4A does not however, translate into comparably high therapeutic efficacy of untargeted liposomes ( [30] and Fig. S4 ). Selectivity of surface-interaction in principle results in maximal in vitro cytotoxicity observed towards target, CD20 + cells (Fig. 4A and Table 2 ). Also, in the presence of low dose (12.5 nM) mitoxantrone IC decreased to about 50% of the value in its absence (Table 2 ).
tL-D and tL-P liposomes reduce Bcl-2 protein level in target cells.
The main function of liposomes as carriers for antisense oligonucleotides is targeted delivery, followed by downregulated level of the protein of interest by the antisense oligonucleotides themselves. As mentioned above, in our model we chose BCL2 as a target gene, which is highly overexpressed in many kinds of leukemia and B-cell lymphomas. We investigated the effect of tL-D and tL-P on Daudi cells. As can be seen in Fig. 4C , both liposomal formulations effectively downregulated the level of Bcl-2 protein in the Daudi cell line after 48 h treatment at a dose of 0.1 mg liposomes/ml (which is equal to 1 μg asODNs anti-BCL2/ml), in contrast to liposomes encapsulating scrambled antisense oligonucleotide sequence at the same concentration, which showed no response. We did not observe significant differences in the silencing abilities of antisense encapsulated in fresh and one year stored liposomal formulations (see Fig. S6 ). Antisense oligonucleotides encapsulated in untargeted liposomes exerted smaller effect on Bcl-2 protein level than these encapsulated in targeted ones. As we previously described [30] the clear inhibition of Bcl-2 mRNA expression in Daudi cells by antisense encapsulated in untargeted liposomes occurs after incubation with 5 μg ODNs/ml.
tL-D and tL-P liposomes induce apoptosis in target cells
Daudi cells were incubated with tL-D, tL-P or control tL-Dsc, tL-Psc at a concentration of 0.1 mg liposomes/ml for 48 h. Apoptosis and necrosis levels in treated cell populations were determined by flow cytometry after Annexin V-FITC and propidium iodide (PI) staining. After 48 h of culture with tL-D and tL-P about 85% of cells were Annexin V and PI positive, indicating that therapeutic activity of the liposomal formulations containing asODNs against BCL2 is based on the induction of apoptosis. In non-target control cells incubated with tL-Dsc and tL-Psc liposomes, only 0.1-2% of the cell populations were Annexin V and PI positive, whereas the major population of cells were Annexin V and PI negative, indicating that they were viable and not undergoing apoptosis (Fig. 4D) .
The effect of tL-D and tL-P liposomes on IL-6 or TNF-α release by human PBMCs is markedly reduced compared to free ODNs
Antisense nucleotides, in particular those containing CpG islands can induce inflammatory and immunological response in patients' cells. We examined if anti-BCL2 asODNs could directly stimulate mononuclear cells isolated from human peripheral blood (PBMCs) to produce cytokines and whether the same ODNs encapsulated in tL-D or tL-P would also exhibit this activity. Levels of IL-6 and TNF-α were determined via ELISA in supernatants obtained from the human PBM cells after 24 and 48 h of incubation with tL-D and tL-P as well as with free asODN. As shown in Fig. 5 , free oligonucleotides exhibit some immunostimulatory effects associated with cytokine IL-6 and TNF-α release. This effect was approximately three to four-fold smaller upon encapsulation of the asODN into tL-D and tL-P liposomes. This ratio remained essentially similar when tested after 24 and 48 h. The results indicate a relatively low immunostimulatory effect of the proposed formulations.
In conclusion, the in vitro assays indicate that the proposed tL-D and tL-P formulations selectively recognize CD20 + cells and induce their apoptosis via BCL2 gene silencing. Moreover, the low doses of mitoxantrone enhanced the effect of liposomes. Finally, when human PBM cells were treated with the proposed formulations, the levels of IL-6 or TNF-α released were remarkably lower compared with the levels released upon treatment of these cells with free asODNs. Blood clearance of the various liposomal formulations was determined as follows. Either DiD-labeled non-PEGylated PE/PC liposomes tL-D, or tL-P liposomes were injected intravenously into Burkitt's lymphoma CD20 + tumor-bearing NOD/SCID mice. As can be seen (Fig. 6A) , the plasma clearance time for the tL-D and tL-P formulations is much longer when compared to that of nonPEGylated liposomes. After i.v. injection of mice, 70-80% of PEG-modified liposomes remained in the circulation for 8 h and approximately 30% remained for 24 h, while less than 20% of PE/PC were detected at 8 h, with only~10% at 24 h. Thus, both proposed tL-D and tL-P preparations fulfill the criteria of long-circulating liposomes. To evaluate the anticancer potential of the proposed longcirculating, targeted liposomal formulations for asODNs, NOD/SCID mice inoculated with the Daudi human Burkitt's lymphoma cell line were used. On day 4 following tumor inoculation, mice with xenografts reaching a volume of 50-70 mm 3 were randomized for different treatments (see Table S1 and Materials and methods section). tL-D or tL-P liposomes or control formulations were injected into the tail veins of each animal group three times at weekly intervals at doses shown in Table S1 . In order to investigate the therapeutic efficacy of the liposomal formulations in combination with a cytostatic, MTO was administered by intraperitoneal (i.p.) injection at a dose of 0.3 mg/kg of body weight into the three groups of animals. The results of this experiment are presented in Fig. 7 and in Fig S2. The data indicate a strong effect of the formulations against tumor development under the in vivo conditions. Mice treated with control preparations including scrambled ODNs sequence developed tumors with a volume of 400-1200 mm 3 observed at 61-70 days following tumor engraftment. It appears that the liposome formulations exerted such a strong effect against this tumor, that therapeutic enhancement due to the combined treatment with a low dose of MTO could not be observed (See Fig. S2 ).
Localization in tumors.
It should be noted that neither the therapeutic antibody itself, used in the concentration corresponding exactly to the concentration present on the tL-D/tL-P formulations (650 μg/kg body weight), nor the same liposome formulations carrying scrambled ODNs affected tumor growth. Also the control L-D and L-P, which were tested here (Fig. S4) showed rather small effect on tumor growth compared to the effect of the tL-D and tL-P formulations reported here. It has to be mentioned that L-D liposomes which were recently published as a formulation named "L-cL" [30] showed reasonable antitumor activity but they were used in multiple weekly injections so to maintain high concentration of formulation. Table 2 Cytotoxicity of tL-D and tL-P formulations towards Daudi cells expressed as IC50 and IC90, determined in the absence or presence of 12.5 nM of mitoxantrone (MTO). Values shown are means ± standard deviation (n = 3). In parentheses the data for both formulations after storage for one year as a suspension at 4°C are shown. Table 1 ), free anti-BCL2 asODNs or free scrambled ODNs for 24 and 48 h. Supernatants were collected and IL-6 (n = 3) and TNF-α (n = 3) release was determined by ELISA analysis. For further details see Materials and methods section.
The experiment also showed no obvious toxicity of either of the liposomal formulations at the intended dose of 0.7 mg ODNs/kg of body weight, as the body weight remained stable during the entire period of experiment (Fig. S1) . Also, histopathological examination of liver, spleen and lung tissues was carried out to test for any damage to the tissue. On day 70 following the start of the experiment and triple iv administration of tL-D or tL-P (at the prescribed doses), animals were sacrificed and tissues were collected. Tissues were sectioned transversely and stained with hematoxylin and eosin. Microphotographs of liver, lung and spleen were taken. Tissues taken from mice administered with PBS were used as a control. No severe pathological effects, such as the appearance of epithelial necrosis or sloughing of epithelial cells, were detected (see Fig. S5 ).
In conclusion, experiments carried out on a human tumor xenograft model characterized by the presence of a specific surface-marker, showed high efficiency of the proposed drug formulation against specific tumor development. Significantly, no obvious side effects could be observed with either preparation.
Discussion
Antisense therapy is considered both a promising and unique strategy amongst many therapeutic approaches to the treatment of neoplastic diseases [31] [32] [33] . Particularly advantageous could be the targeted delivery of asODNs to specific cells. The aim of the present study was to construct the DOTAP-and PEI-based liposomal carriers of antisense oligodeoxynucleotides which could be targeted via coating with a specific antibody. Our model was acute lymphoblastic leukemia (ALL) or lymphoma, a CD20+ cell-based pathology in which overexpression of the BCL-2 gene is observed. Although use of similar components in monotherapies or in combined therapy has been reported in the literature, our formulations showed very high therapeutic efficiency along with only limited adverse immunostimulatory effect that is usually associated with the antisense oligonucleotide component drug (asODNs) [34] [35] [36] [37] [38] [39] . Our CD20 targeted liposomes were preferentially uptaken by B-cells, resulting in downregulated BCL2 expression and sensitization of the target cells to cytostatics in vitro. Moreover, our results demonstrate an in vivo therapeutic efficacy for B-cell malignancy of CD20 targeted delivery of antisense nucleotide-based drug against BCL2, encapsulated in the immunoliposomes described here. The enhanced retention effect enables liposomes and other particles smaller than 400 nm in size to penetrate the tumor-associated endothelia and extravasate into the tumor tissue [40] . Consequently, nanoparticle-based drug delivery systems with a defined size range of 10-200 nm are commonly used [41] . However, in the case of nontargeted liposomes, the therapeutic efficacy observed in the animal model used by our laboratory was limited ( [30] and Fig. S4 ). The two liposomal constructs presented in this study, namely, tL-D and tL-P, were characterized by a homogenous particle size of approximately 120 nm and a positive zeta potential of 22 and 5 mV, respectively. The differences in the values of the zeta potential between the two liposome formulations arise from the physicochemical properties of the complexing agents used for the asODNs, namely, DOTAP or PEI. DOTAP, as a cationic lipid, is able to incorporate into the lipid bilayer, which may account for the higher positive zeta potential than the tL-P formulation, despite both formulations having the same liposomal bilayer composition. These two parameters remained essentially stable for both liposome formulations during long-term (12 months) storage. The barrier properties of both preparations facilitated the preservation of the nucleic acid component against externally added nucleases. Moreover, the formulations described in these studies are stable in the presence of human serum. Similar properties were previously observed for the "L-cL" formulation, despite the significant differences in the chemical composition and the lipid molar ratio [30] . In addition, the tL-D and tL-P formulations presented in this study essentially did not show hemolytic activity and were characterized by low non-specific cytotoxicity (Fig. 3 A, B) . As both formulations are based on a DSPE-PEG enriched bilayer, they should remain in the circulation for the extended periods. Modification with PEG improves the pharmacokinetics and pharmacodynamics of liposomes by reducing renal clearance, protecting from enzymatic degradation and limiting immunogenic and antigenic reactions. Due to the availability of a range of PEG derivatives and PEG conjugation technologies, PEGylation strategies could potentially be adapted for each particular application [42] [43] [44] [45] [46] . Indeed, model animal experiments have consistently shown markedly increased circulation times for PEG-derived liposome formulations, supporting the vital hypothesis that both formulations fulfill the criteria of long-circulating liposomes (Fig. 6 ).
As a model for testing the properties of the proposed liposomal formulations we chose the BCL2 gene as a target for downregulation of expression and CD20+ cancer cells as a specific target. Antisense nucleotides against BCL2, with a sequence corresponding to G3139, along with a commercially available antibody, Rituximab (mouse:human chimeric IgG1 anti-CD20 antibody), were chosen as specific formulation agents defining the target of the drug. It should be noted that our formulations could also be used as a nucleic acid delivery vehicle in other systems for which the specific genes and surface markers are known. By way of example, in the case of breast cancer, such a targeted delivery system could exploit the antisense modulation of expression levels of one of IAP genes with Trastuzumab, as a cell-targeting moiety, respectively. The IAP family members, such as BIRC5 (baculoviral IAP repeat containing 5), XIAP, cIAP1 and cIAP2 are overexpressed in breast cancer cell lines or tumors [47] . Currently, antisense oligonucleotides against BIRC5 (LY2181308) [48] and XIAP (AEG 35156) [49] are in Phase II of Clinical Trials, and could be used as a genetic drug in breast cancer treatment [50] . In addition HER2 is overexpressed in approximately 20% of all breast cancers. Trastuzumab, which is a humanized monoclonal antibody against HER2, has been the first to reach widespread clinical use, particularly for the treatment of metastatic breast cancer. Resistance to Trastuzumab is a major clinical problem in the treatment of HER2-overexpressing breast cancer. Molecular mechanism can be associated with up-regulation of anti-apoptotic proteins, such as Bcl-2 [51] . As previously described, the HER2 aptamer-Bcl-2 siRNA conjugates selectively internalize into HER2-breast cancer cells and silence Bcl-2 gene expression [52] . What is more, liposomes targeted via antibodies against HER2 receptor enhanced the biological activity of antisense ODNs against Bcl-2 in BT-474 human breast cancer cell line. No antisense effect on cellular level of protein expression was detected when ODN was associated with PEG-coated cationic liposomes. On the contrary, when the corresponding HER2-targeted ODN delivery system was used, a 46% inhibition of Bcl-2 expression was observed [53] .
Again, a similar strategy could be used against acute lymphoblastic leukemia (ALL) in patients with the Philadelphia chromosome (Ph). The Philadelphia translocation t(9;22)(q34;q11) generates the bcr-abl fusion gene, characteristic for chronic myelogenous leukemia (CML) and Ph + acute lymphoblastic leukemia (ALL) [54] . In the case of ALL, the presence of the Ph translocation is tightly correlated with poor prognosis. Small interfering RNAs (siRNAs) or asODNs could be designed to target the bcr-abl oncogene, which causes bcr-abl-positive acute lymphoblastic leukemia. ALL blast cells express a variety of specific antigens, such as CD19, CD20, CD22, CD33, and CD52, that could serve as biomarker-targets for mAbs [55] . A number of commercially available antibodies such as anti-CD52 (alemtuzumab), anti-CD22 (epratuzumab), and anti-CD33 (gemtuzumab) are already available in the clinic that could be used in this regard to target liposomes specifically to those cells expressing the respective biomarker.
The system of Rituximab and asODNs against BCL2 is a widely explored strategy in the treatment of B-cell malignancies. However, Gekeler et al. [38] demonstrated that the asODN, G3139, contains two dinucleotide CpG motifs and therefore acted as a potent immunostimulator in the TLR9 murine model [38] . Yu and co-workers [56] , studying reasons for the limited success of G3139, suggested that this was due to the low intracellular levels of G3139 achieved in the patient and the potential stimulation of cells and cytokine release via the CpGs through TLRs. These authors designed Rituximab-targeted immunoliposomal nanoparticles, "RIT-INPs", as carrier for the G3139 antisense oligonucleotide. They used protamine as a complexing agent, and a liposomal bilayer composed of ePC, DC-CHOL, DSPE-PEG. G3139 encapsulated in immunoliposomal nanoparticles targeted with Rituximab (RIT-INPs) showed reduced immunostimulation and high therapeutic efficacy in the Raji xenograft NOD/SCID model in vivo [56] . The data presented in our study (Fig. 5 ) indicate substantial limitation in IL-6 or TNF-α release in human PBM cells after treatment with tL-D or tL-P, compared to free anti-BCL2 asODNs. In addition, we used unmodified oligonucleotides, so there is no possible sequenceindependent toxicity due to usage of phosphorothioate-modified oligonucleotides [57, 58] . Immunoliposomes decorated with antibodies against CD20 or CD19 have been described previously. For example, Sapra et al. [59, 60] demonstrated improved results of treatment of tumor-bearing mice with liposome-encapsulated doxorubicin or vincristine, targeted via anti-CD19 or anti-CD20 antibodies, or their derivatives. Taking into account our previous data [30] alongside the results presented here, targeting via specific antibodies significantly improves the therapeutic activity of liposome-encapsulated asODNs.
Based on the findings of both our own studies and of other promising preclinical data [56] , it would appear that further clinical development of liposomal formulations of asODNs against BCL2, such as tL-D and tL-P, could provide the basis for a highly improved therapeutic intervention in the case of ALL. Drug resistance is a serious limiting factor in the treatment of cancer. Overexpression of the BCL2 gene is one of the mechanisms responsible for drug resistance, particularly in human lymphoblastic leukemia of B-cells. For these types of leukemia a more sophisticated therapeutic strategy needs to be used. One of the reasons to undertake gene-silencing therapy in leukemia treatment is sensitizing these cells to standard chemotherapy. Our in vitro experiments showed an increase of efficacy of a standard cytostatic observed in the case of Daudi cells (see Table 2 ). However, targeted delivery of asODNs against the BCL2 gene, by using the tL-D or tL-P liposomal formulations as well as silencing this gene resulted in such a substantial efficacy in its own right that the expected synergistic effect in the presence of the cytostatic was not observed (see Fig. S2 ).
The in vitro results presented above, using either the tL-D or tL-P formulations, provided a starting point for investigating the behavior of these formulations in animal studies. For these experiments we used NOD/SCID mice bearing a Daudi tumor xenograft (human Burkitt's lymphoma) as a human tumor xenograft model. For the pharmacokinetics and biodistribution studies, we used liposomal formulations labeled with lipid-binding dye. The lipophilic carbocyanines, such as DiD, are weakly fluorescent in water but highly fluorescent when incorporated into membranes. We have observed only a small (b 5%) transfer of DiD from liposomes to red blood cells (Tab. S2), indicating that transfer of free dye between liposomes and cells is rather limited. After 24 h, about 30% of the injected drug incorporated within the immunoliposomal shell was still present in the blood (Fig. 6A) . Accumulation of immunoliposomes in the tumor could also be observed (Fig. 6B) . Therefore, the biodistribution data indicated that both tL-D and tL-P liposomal formulations were able to reach and accumulate within their target site (Fig. 6B) . Moreover, the downregulation of BCL2 gene expression in the tumors was observed after the same time interval (Fig. 6C) , confirming the specificity of action of the proposed formulations. The results of the experiment on engrafted tumor treatment with the tL-D and tL-P encapsulated asODNs indicate that both liposomal formulations are able to inhibit tumor growth by 100%, leading to complete remission in treated mice (Fig. 7) .
The data revealed a very high therapeutic activity of both tL-D and tL-P liposomal formulations carrying encapsulated antisense oligonucleotides against BCL2 gene under in vivo conditions. Multiple negative controls, such as PBS, Rituximab (650 μg/kg), tL-Dsc, and tL-Psc, excluded the antitumor activity of each of the liposomal components separately. Although some cytotoxicity towards non-target cells could be observed in vitro, no toxicity was observed in the animal models in vivo, suggesting that the liposomal formulations (i.e. lipid bilayer components and complexing agents, DOTAP or PEI) were non-toxic at the doses used, as no weight-loss, nor any changes in the histology of major organs was observed in the experimental animals ( Fig. S1 and  S5 ). Taking all of the above considerations into account, it is concluded that both of the proposed tL-D and tL-P liposomal formulations encapsulating antisense oligodeoxynucletides against BCL2 gene expression appear to demonstrate proof-of-concept for the targeted treatment of CD20 + cell-based pathologies. While the combination of these liposome formulations with cytotoxic drugs might be the ultimate approach, it is particularly encouraging to note that the current study demonstrated the effectiveness of such a targeted-liposome approach even as a monotherapy.
Conclusions
Two formulations of immunoliposomes are proposed in this study, consisting of a core of antisense oligonucleotides complexed with either a cationic lipid, 1,2-dioleoyl-3-trimethylammonium-propane, or a synthetic polycation, polyethyleneimine, encapsulated within liposomes containing a polyethylene-glycol-derivative of distearoyl phosphatidylethanolamine. The liposomes were modified with covalently-bound antibodies recognizing CD20, a well-characterized bio-marker present on the surface of leukemia and lymphoma cells. These liposomes maintain stability for at least one year of storage in suspension, or, as a freezedried powder and effectively protect the encapsulated nucleic acids. Immunoliposomes developed in our studies effectively reduce the level of Bcl-2 protein in cancer cells and are selective towards target cells. In vivo experiments carried out on mice-engrafted tumors characterized by the presence of the specific CD20 bio-marker showed highly specific efficiency of the drug formulation against tumor development.
Although single components of the proposed formulations, such as antisense oligonucleotides and monoclonal antibodies have been used in other studies, or have been under clinical trials, the mixed formulations proposed here showed a high therapeutic efficacy with only a limited immunostimulatory effect that asODNs have traditionally suffered from.
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